-
Cutia Therapeutics’ CU-10201 Receives NMPA Approval for Acne Vulgaris Treatment
•
Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced that its CU-10201, a 4% minocycline foam agent for external use, has received market approval from the National Medical Products Administration (NMPA) in China. The approval is for the treatment of non-nodular moderate to severe acne vulgaris in individuals…
-
Cutia Therapeutics’ CU-30101 NDA Accepted for Review by China’s NMPA
•
Cutia Therapeutics (HKG: 2487), a company specializing in dermatological treatments, has announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for CU-30101, a topical lidocaine and tetracaine cream. This pharmaceutical product is designed to provide rapid and long-lasting anesthetic effects, leveraging the…
-
Cutia Therapeutics Submits New Drug Application for Androgenic Alopecia Treatment in Hong Kong
•
Cutia Therapeutics (HKG: 2487), a dermatology-focused pharmaceutical company, has announced the submission of a New Drug Application (NDA) for its proprietary CU-40102 (external einasteride spray) for the treatment of androgenic alopecia to the Department of Health of Hong Kong, China. CU-40102 is positioned as the world’s first and currently only…
-
Cutia Therapeutic’s CU-20401 Shows Promising Safety and Efficacy in Phase I Abdominal Fat Reduction Study
•
Cutia Therapeutic (HKG: 2487), a China-based dermatology specialist, has announced the successful completion of a Phase I study for its potential Category 1 drug CU-20401, a recombinant mutant collagenase, which is being investigated for the treatment of abdominal fat accumulation. The single-center, open-label, placebo-controlled, dosage-escalation study enrolled 48 subjects in…
-
Cutia Therapeutics Achieves Primary Endpoint in Phase I Study of CU-40101 for Androgenic Alopecia
•
Cutia Therapeutics (HKG: 2487), a company specializing in dermatological therapies, has announced that its Phase I clinical study for CU-40101, a small-molecule thyroid hormone receptor agonist liniment for external use in androgenic alopecia in China, has successfully reached its primary endpoint. Study Design and ResultsThe Phase I study was a…
-
Cutia Therapeutics’ CU-20401 Completes Phase I Study for Obesity Treatment
•
China-based dermatology specialist Cutia Therapeutics (HKG: 2487) has announced the last subject out (LSO) in a Phase I study for its potential Category 1 drug, CU-20401. This recombinant mutant collagenase is being developed for the treatment of obesity and other metabolic diseases related to local fat accumulation, marking a significant…
-
Cutia Therapeutics Files for Market Approval of CU-10201 with NMPA for Acne Treatment
•
Cutia Therapeutics (HKG: 2487), a developer focused on dermatology therapies, has announced the submission of a market approval filing for its CU-10201 (4% minocycline foam agent for external use) to the National Medical Products Administration (NMPA) in China. The drug, which targets the treatment of non-nodular moderate to severe acne…
-
Cutia Therapeutics’ CU-40102 Meets Primary Endpoint in Phase III Study for Androgenic Alopecia
•
Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has announced that its Phase III clinical study for CU-40102 (external einasteride spray) in androgenic alopecia in China has successfully reached its primary endpoint. Study Design and Patient EnrollmentThe multi-center, randomized, double-blind, placebo-controlled Phase III regulatory study was designed to assess the efficacy…
